Substantial improvements in cancer trials not likely caused by placebo effects

December 31, 2002

An analysis of placebo effects in randomized double-blinded placebo-controlled trials of cancer treatments has found that placebos are sometimes associated with improved control of symptoms such as pain and appetite but rarely with objective tumor response. The findings appear in a review article in the January 1 issue of the Journal of the National Cancer Institute.

The placebo effect is an effect seen in patients given an intervention, such as a placebo, that has no pharmacologically-mediated action against the disease. Previous studies have suggested that some cancer patients who had received a placebo for pain reported a reduction in pain after the intervention.

To determine the probability that a placebo will lead to improvement of symptoms and tumor response, Gisèle Chvetzoff, M.D., of the Centre Léon Bérard in Lyon, France, and Ian F. Tannock, M.D., Ph.D., of the Princess Margaret Hospital in Toronto, reviewed reports of 37 randomized controlled trials that compared a group receiving active treatment with a group receiving a placebo. The authors also reviewed reports of 10 randomized controlled trials that compared a group receiving active treatment plus best supportive care with a group receiving best supportive care alone. Some of the trials looked at individual responses, and other trials looked at group responses.

The researchers found that, in trials that examined average responses for patients in the placebo group, two of six trials reported improvements in pain and one of seven trials reported improvements in appetite. No trials reported improvements in average levels of weight gain, quality of life, or performance status.

In trials that looked at individual response to placebos, 0% to 21% of patients given a placebo showed improvement in pain or decreased use of pain medications, 8% to 27% of patients showed an improvement in appetite, 7% to 17% of patients showed weight gain, and 6% to 14% of patients showed improvement in performance status. By contrast, objective tumor response was observed in 2% to 7% of patients in a placebo group.

In addition, the authors found that the likelihood of symptom improvement in patients receiving best supportive care was similar to that of patients receiving placebo.

"The present review suggests that substantial well-documented patient-reported improvement in symptom control or quality of life (particularly when supported by objective evidence of tumor response) are unlikely due to placebo effects," the authors conclude. They add that they strongly support the use of a double-blind placebo-controlled design for randomized trials whenever possible because such a design can ensure equal conditions in both arms and minimize various types of bias.

In an accompanying editorial, Robert J. Temple, M.D., of the Center for Drug Evaluation and Research at the U.S. Food and Drug Administration, points out that only two of 10 trials reported objective tumor responses of more than 2% in the placebo group (one trial reported 7%). He says that "tumor response rates of more than 10% are unlikely to be seen in an untreated group and can therefore be considered evidence of a drug effect... ."

Temple also notes that in trials looking at symptoms such as pain and appetite, individual patient improvements were seen among people in placebo groups, suggesting that single-arm trials (those that include only a treatment group) are a suboptimal way to assess the benefits of treatment.
-end-
Contact: Vince Rice, Princess Margaret Hospital, 416-946-4501 ext. 5771; fax: 416-946-4585, vince.rice@uhn.on.ca

Editorial: Christine Parker, Center for Drug Evaluation and Research, FDA, 301-827-7251, parkerc@cder.fda.gov, or Crystal Rice, 301-827-1673. ricec@cder.fda.gov

Chvetzoff G, Tannock I. Placebo effects in oncology. J Natl Cancer Inst 2003;95:19-29.

Editorial: Temple R. Implications of effects in placebo groups. J Natl Cancer Inst 2003;95:2-3.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Journal of the National Cancer Institute

Related Weight Gain Articles from Brightsurf:

How much postmenopause weight gain can be blamed on weight-promoting medications?
Abdominal weight gain, which is common during the postmenopause period, is associated with an array of health problems, including diabetes and heart disease.

Earlier gestational diabetes diagnosis, less weight gain
A new study has shown that initiating screening for gestational diabetes in high-risk women in the first trimester of pregnancy instead of the second trimester, allowing for treatment to start earlier, can help optimize gestational weight gain.

Research provides new insights into menopause and weight gain
Can women in menopause get the benefits of hormone replacement therapy without the health risks?

Study examines timing of weight gain in children
Recent studies suggest kids tend to gain the most weight in summer, but schools are chastised for providing unhealthy food and beverages, along with decreasing opportunities for physical activity.

New study shows why people gain weight as they get older
Many people struggle to keep their weight in check as they get older.

Being teased about weight linked to more weight gain among children, NIH study suggests
Youth who said they were teased or ridiculed about their weight increased their body mass by 33 percent more each year, compared to a similar group who had not been teased, according to researchers at the National Institutes of Health.

Daily self-weighing can prevent holiday weight gain
Researchers at the University of Georgia have shown that a simple intervention -- daily self-weighing -- can help people avoid holiday weight gain.

Association between weight before pregnancy, weight gain during pregnancy and adverse outcomes for mother, infant
An analysis that combined the results of 25 studies including nearly 197,000 women suggests prepregnancy body mass index (BMI) of the mother was more strongly associated with risk of adverse maternal and infant outcomes than the amount of gestational weight gain.

Comfort food leads to more weight gain during stress
Australian researchers have discovered a new molecular pathway in the brain that triggers more weight gain in times of stress.

Women gain weight when job demands are high
Heavy pressures at work seem to predispose women to weight gain, irrespective of whether they have received an academic education.

Read More: Weight Gain News and Weight Gain Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.